JP2017510641A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017510641A5 JP2017510641A5 JP2017502932A JP2017502932A JP2017510641A5 JP 2017510641 A5 JP2017510641 A5 JP 2017510641A5 JP 2017502932 A JP2017502932 A JP 2017502932A JP 2017502932 A JP2017502932 A JP 2017502932A JP 2017510641 A5 JP2017510641 A5 JP 2017510641A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- nitrogen
- independently selected
- oxygen
- sulfur
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461971023P | 2014-03-27 | 2014-03-27 | |
| US61/971,023 | 2014-03-27 | ||
| PCT/US2015/022841 WO2015148854A1 (en) | 2014-03-27 | 2015-03-26 | Substituted indole mcl-1 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017510641A JP2017510641A (ja) | 2017-04-13 |
| JP2017510641A5 true JP2017510641A5 (enExample) | 2018-05-17 |
| JP6757312B2 JP6757312B2 (ja) | 2020-09-16 |
Family
ID=54196421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502932A Active JP6757312B2 (ja) | 2014-03-27 | 2015-03-26 | 置換インドールｍｃｌ−１阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10533010B2 (enExample) |
| EP (1) | EP3122353B1 (enExample) |
| JP (1) | JP6757312B2 (enExample) |
| CN (1) | CN106456602B (enExample) |
| AU (1) | AU2015235944B2 (enExample) |
| CA (1) | CA2943815C (enExample) |
| WO (1) | WO2015148854A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6757312B2 (ja) | 2014-03-27 | 2020-09-16 | ヴァンダービルト ユニバーシティー | 置換インドールｍｃｌ−１阻害剤 |
| US9949965B2 (en) | 2014-10-17 | 2018-04-24 | Vanderbilt University | Tricyclic indole Mcl-1 inhibitors and uses thereof |
| US11306107B2 (en) | 2016-02-25 | 2022-04-19 | Amgen Inc. | Compounds that inhibit MCL-1 protein |
| AU2017228385B2 (en) * | 2016-03-04 | 2021-11-04 | Vanderbilt University | Substituted indole Mcl-1 inhibitors |
| WO2017182625A1 (en) | 2016-04-22 | 2017-10-26 | Astrazeneca Ab | Macrocyclic mcl1 inhibitors for treating cancer |
| WO2017198341A1 (en) | 2016-05-19 | 2017-11-23 | Bayer Aktiengesellschaft | Macrocyclic indole derivatives |
| CN109715632B (zh) * | 2016-05-19 | 2021-10-26 | 拜尔公开股份有限公司 | 大环吲哚衍生物 |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| JP6453507B2 (ja) * | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| US20200062738A1 (en) * | 2017-04-30 | 2020-02-27 | Development Center For Biotechnology | Anti-cancer stemness drugs |
| WO2019040511A1 (en) * | 2017-08-22 | 2019-02-28 | University Of Maryland Batimore | DOUBLE INHIBITORS OF BCL-2 AND HDM2 FAMILIES BY CO-MIMETTISM OF ALPHA BH3 AND P53 PROPELLERS |
| WO2019096909A1 (en) | 2017-11-17 | 2019-05-23 | The Broad Institute, Inc. | Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer |
| UY37972A (es) | 2017-11-17 | 2019-06-28 | Bayer Pharma AG | Derivados de indol macrocíclicos sustituidos con cloro |
| WO2019096914A1 (en) | 2017-11-17 | 2019-05-23 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
| US20210253598A1 (en) | 2017-11-17 | 2021-08-19 | Bayer Aktiengesellschaft | Aryl annulated macrocyclic indole derivatives |
| JP7234250B2 (ja) | 2017-11-17 | 2023-03-07 | バイエル アクチェンゲゼルシャフト | 置換大環状インドール誘導体 |
| UY37973A (es) | 2017-11-17 | 2019-06-28 | Bayer Ag | Derivados de indol macrocíclicos |
| CN109988151B (zh) * | 2017-12-29 | 2021-04-23 | 北京赛特明强医药科技有限公司 | 一种炔类化合物、制备方法及其应用 |
| US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| CN108251104B (zh) * | 2018-02-27 | 2019-11-05 | 山东大学 | 一种取代吲哚-2-羧酸类Bcl-2小分子荧光探针及其应用 |
| DK3793565T3 (en) * | 2018-05-14 | 2022-03-07 | Gilead Sciences Inc | Mcl-1-inhibitorer |
| WO2020003119A1 (en) * | 2018-06-25 | 2020-01-02 | Suzhou Mednes Pharma Tech Co., Ltd. | Compounds and methods for treatment of hedgehog pathway associated conditions |
| BR112021005655A2 (pt) * | 2018-09-27 | 2021-06-29 | Pierre Fabre Medicament | ligantes à base de sulfomaleimida e conjugados correspondentes |
| TWI749404B (zh) * | 2018-11-22 | 2021-12-11 | 大陸商蘇州亞盛藥業有限公司 | 作為mcl-1抑制劑的大環吲哚 |
| US11498928B2 (en) | 2019-01-18 | 2022-11-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic spiroethers as Mcl-1 inhibitors |
| EP3969457B1 (en) | 2019-05-17 | 2025-08-13 | The Broad Institute Inc. | Methods of preparing macrocyclic indoles |
| WO2021092061A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Combination treatment for senescence-associated diseases |
| WO2021092053A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| WO2024123195A1 (en) * | 2022-12-06 | 2024-06-13 | Captor Therapeutics S.A. | Targeted protein degradation using prodrugs of bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein |
| WO2024121256A1 (en) * | 2022-12-06 | 2024-06-13 | Captor Therapeutics S.A. | Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein |
| WO2025104079A1 (en) * | 2023-11-17 | 2025-05-22 | Helmholtz-Zentrum für Infektionsforschung GmbH | Salicylic acid and picolinic acid derivatives as inhibitors of energy coupling factor (ecf) transporters for the treatment of bacterial infections |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4703053A (en) | 1985-10-28 | 1987-10-27 | Warner-Lambert Company | Benzothiophenes and benzofurans and antiallergic use thereof |
| GB8531612D0 (en) | 1985-12-23 | 1986-02-05 | Beecham Wuelfing Gmbh & Co Kg | Compounds |
| US4994477A (en) * | 1988-03-24 | 1991-02-19 | Abbott Laboratories | Heterocyclic renin inhibitors |
| DE4128015A1 (de) | 1991-08-23 | 1993-02-25 | Kali Chemie Pharma Gmbh | 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel |
| EP0639573A1 (de) | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament |
| US5436264A (en) | 1993-08-19 | 1995-07-25 | Syntex (U.S.A.) Inc. | N-aryloxyalkyl tryptamine α1 -adrenergic receptor antagonists |
| JP3739432B2 (ja) | 1994-02-25 | 2006-01-25 | ダイセル化学工業株式会社 | オゾン開裂反応 |
| AU2651297A (en) | 1996-05-08 | 1997-11-26 | Ihara Chemical Industry Co. Ltd. | Indolyl-substituted uracil derivatives and herbicides comprising them as active ingredients |
| AU738048B2 (en) | 1996-09-12 | 2001-09-06 | Idun Pharmaceuticals, Inc. | Inhibition of apoptosis using interleukin-1beta-converting enzyme (ICE)/CED-3 family inhibitors |
| FR2761070B1 (fr) * | 1997-03-20 | 1999-04-23 | Synthelabo | Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique |
| FR2761073B1 (fr) * | 1997-03-20 | 1999-04-23 | Synthelabo | Derives de pyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique |
| US6500853B1 (en) | 1998-02-28 | 2002-12-31 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| CA2427499A1 (en) | 2000-10-10 | 2002-04-18 | Smithkline Beecham Corporation | Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-.gamma. binding agents |
| FR2827287B1 (fr) | 2001-07-13 | 2003-10-31 | Servier Lab | Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP1689389A4 (en) | 2003-12-04 | 2009-06-17 | Nat Health Research Institutes | INDOLE COMPOUNDS |
| US7429611B2 (en) | 2004-09-23 | 2008-09-30 | Bristol-Myers Squibb Company | Indole inhibitors of 15-lipoxygenase |
| US8097644B2 (en) | 2006-03-28 | 2012-01-17 | Allergan, Inc. | Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist |
| DE102006033109A1 (de) | 2006-07-18 | 2008-01-31 | Grünenthal GmbH | Substituierte Heteroaryl-Derivate |
| KR20090096690A (ko) | 2006-12-14 | 2009-09-14 | 아스텔라스세이야쿠 가부시키가이샤 | Ｃｒｔｈ2 길항제 및 항알레르기제로 유용한 폴리사이클릭 산 화합물 |
| EP2134685B1 (en) | 2007-04-16 | 2015-09-02 | AbbVie Inc. | 7-nonsubstituted indole derivatives as mcl-1 inhibitors |
| ES2705599T3 (es) * | 2007-04-16 | 2019-03-26 | Abbvie Inc | Indoles sustituidos en la posición 7 como inhibidores de mcl-1 |
| US20090270497A1 (en) | 2008-04-24 | 2009-10-29 | Pharmacyclics, Inc. | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors |
| EP2161266A1 (en) | 2008-08-22 | 2010-03-10 | EVOTEC Neurosciences GmbH | Benzofuran derivatives as orexin receptor antagonists |
| WO2010068684A2 (en) | 2008-12-09 | 2010-06-17 | Dana Farber Cancer Institute, Inc. | Methods and compositions for specific modulation of mcl-1 |
| FR2961393B1 (fr) | 2010-06-16 | 2013-02-15 | Oreal | Procede de coloration capillaire a partir d'une composition comprenant au moins un compose indolique ou une indolinique, un sel metallique, du peroxyde d'hydrogene et un agent alcalinisant |
| AU2011299551A1 (en) | 2010-09-08 | 2013-03-21 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | P53-Mdm2 antagonists |
| WO2012120500A2 (en) | 2011-03-06 | 2012-09-13 | Merck Serono S.A. | Low fucose cell lines and uses thereof |
| CA2857193A1 (en) | 2011-11-29 | 2013-06-06 | Beta Pharma Canada Inc. | Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents |
| WO2013112878A1 (en) | 2012-01-26 | 2013-08-01 | The Penn State Research Foundation | Mcl-1 modulating compositions |
| US10093640B2 (en) | 2012-09-21 | 2018-10-09 | Vanderbilt University | Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors |
| CA2922341C (en) * | 2013-08-28 | 2022-06-07 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| JP6757312B2 (ja) | 2014-03-27 | 2020-09-16 | ヴァンダービルト ユニバーシティー | 置換インドールｍｃｌ−１阻害剤 |
| US9949965B2 (en) | 2014-10-17 | 2018-04-24 | Vanderbilt University | Tricyclic indole Mcl-1 inhibitors and uses thereof |
| AU2017228385B2 (en) | 2016-03-04 | 2021-11-04 | Vanderbilt University | Substituted indole Mcl-1 inhibitors |
-
2015
- 2015-03-26 JP JP2017502932A patent/JP6757312B2/ja active Active
- 2015-03-26 WO PCT/US2015/022841 patent/WO2015148854A1/en not_active Ceased
- 2015-03-26 EP EP15768818.5A patent/EP3122353B1/en active Active
- 2015-03-26 US US15/129,042 patent/US10533010B2/en active Active
- 2015-03-26 CN CN201580028206.8A patent/CN106456602B/zh active Active
- 2015-03-26 AU AU2015235944A patent/AU2015235944B2/en not_active Ceased
- 2015-03-26 CA CA2943815A patent/CA2943815C/en active Active
-
2019
- 2019-11-19 US US16/688,872 patent/US11208415B2/en active Active
-
2021
- 2021-11-04 US US17/518,732 patent/US12195472B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017510641A5 (enExample) | ||
| CN110776507B (zh) | Bcl-2抑制剂与化疗药的组合产品及其在预防和/或治疗疾病中的用途 | |
| CN110772639B (zh) | Bcl-2抑制剂与MDM2抑制剂的组合产品及其在预防和/或治疗疾病中的用途 | |
| JP7028809B2 (ja) | コルテキソロン１７α－バレレートを含む腫瘍治療に用いるための組成物 | |
| CN105163584B (zh) | 用于治疗癌症的化合物 | |
| JP2019516759A5 (enExample) | ||
| JP2013529200A5 (enExample) | ||
| JP2013526540A5 (enExample) | ||
| RU2019101220A (ru) | Кристаллические формы соединения триазолопиримидина | |
| JP2013529199A5 (enExample) | ||
| BR112013002375B1 (pt) | Composto, processo de preparação do mesmo, composição farmacêutica, e, usos de um composto | |
| US12312334B2 (en) | Quinoxaline compounds and uses thereof | |
| JP2019529475A5 (enExample) | ||
| AU2016301212A1 (en) | Inhibitors of ACK1/TNK2 tyrosine kinase | |
| CN104755455B (zh) | 可用于治疗癌症的巨大戟醇衍生化合物 | |
| CN104470509A (zh) | 剂量范围在2至30mg/kg的地塞米诺或其衍生物在癌症治疗中的用途 | |
| CN102573833A (zh) | 癌细胞凋亡 | |
| ES2779465T3 (es) | Compuesto para el tratamiento o la prevención del cáncer de mama | |
| TW202406903A (zh) | 聯芳組成物和調控激酶級聯之方法 | |
| US20190151306A1 (en) | Mdr-reversing 8-hydroxy-quinoline derivatives | |
| CN107638426B (zh) | 噻唑类化合物在制备治疗肿瘤的药物中的用途 | |
| JP2020533399A (ja) | 新規低分子化合物 | |
| TW201231470A (en) | 4-anilinofuro[2,3-b]quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | |
| TWI594982B (zh) | 低細胞毒性血管阻斷劑 | |
| CN115466205B (zh) | 分离的3-（2-溴-3,4-二羟基-苯基）-n-（3,4,5-三羟基-苄基）-硫代丙烯酰胺的反式异构体 |